- Conditions
- Acute Heart Failure, Decompensated Heart Failure
- Interventions
- subcutaneous furosemide and sc2wear device
- Combination Product
- Lead sponsor
- Adrian Hernandez
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 16
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,233
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Tak-228 & Tak-117, Cisplatin & Nab Paclitaxel
- Drug
- Lead sponsor
- Joyce O'Shaughnessy
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Tongue Tumor, Tongue Cancer
- Interventions
- CT Scan, Experimental Oral Stent Device
- Diagnostic Test · Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Kidney Transplant Failure and Rejection
- Interventions
- Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- docetaxel, LY2181308 sodium, Prednisone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Heart Failure, Acute Decompensated Heart Failure
- Interventions
- Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor
- Combination Product
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Postoperative Pain
- Interventions
- Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management
- Drug
- Lead sponsor
- Inova Health Care Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
- Interventions
- Pentoxifylline, Placebo, Tocopherol
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more
- Conditions
- Differentiated Thyroid Cancer
- Interventions
- rhTSH
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Interventions
- Ivabradine, Ivabradine Placebo, Coordinated Care, Usual Care
- Drug · Behavioral
- Lead sponsor
- Kanecia Obie Zimmerman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Cancers
- Interventions
- Fentanyl Sublingual Spray, Shuttle Walk Test, Questionnaires, Mental Ability Tests, Phone Call
- Drug · Procedure · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
- Interventions
- Varespladib Methyl, Placebo, Standard of care (SOC)
- Drug
- Lead sponsor
- Ophirex, Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more
- Conditions
- Advanced Gastric Cancer
- Interventions
- Everolimus, Everolimus placebo, Best Supportive Care (BSC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Fayetteville, Arkansas • Redlands, California • Detroit, Michigan + 5 more
- Conditions
- Gastrointestinal Microbiome, Neoplasm, Colorectal
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Overactive Bladder
- Interventions
- Macrobid® Capsules 100 mg, Standard Medical Care (SMC)
- Drug · Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Kidney Transplantation
- Interventions
- CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Episodic Migraine
- Interventions
- Standard of Care (SOC) Migraine Preventive Medication, Atogepant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 112
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 100 more
- Conditions
- Transplant, Kidney
- Interventions
- Mycophenolate mofetil + Tacrolimus, Mycophenolate mofetil + Cyclosporin
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)
- Interventions
- Darlifarnib, Cabozantinib, Adagrasib
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
- Conditions
- Primary Progressive Aphasia, PPA
- Interventions
- Active tDCS plus Speech-Language Therapy, Sham tDCS plus Speech-Language Therapy
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
- Interventions
- CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7
- Drug · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Abortion Early
- Interventions
- Atorvastatin, Misoprostol
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Glioblastoma, Surgery, High Grade Glioma
- Interventions
- Neoadjuvant chemoradiation, Drug Therapy with Temozolomide (benzolamide) (Standard of Care), Surgery post Radiation and Temozolomide (benzolamide)
- Radiation · Drug · Procedure
- Lead sponsor
- Geisinger Clinic
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- semaglutide, oral glucose-lowering medications (commercially available)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,018 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 25
- States / cities
- Alhambra, California • Costa Mesa, California • La Jolla, California + 20 more